Roger J BrÃ¼ggemann

List of Publications by Year
in descending order

171 papers	8,471 citations	53660 45 h-index	54797 84 g-index
175 all docs	175 docs citations	175 times ranked	8784 citing authors

#	Article	IF	Citations
1	Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clinical Microbiology and Infection, 2018, 24, e1-e38.	2.8	942
2	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infectious Diseases, The, 2021, 21, e149-e162.	4.6	586
3	Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents. Clinical Infectious Diseases, 2009, 48, 1441-1458.	2.9	368
4	Tackling the emerging threat of antifungal resistance to human health. Nature Reviews Microbiology, 2022, 20, 557-571.	13.6	311
5	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Medicine, 2020, 46, 1524-1535.	3.9	278
6	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates, 2015, 21-22, 30-40.	6.5	262
7	Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. ELife, 2020, 9, .	2.8	235
8	Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium. JAMA - Journal of the American Medical Association, 2018, 319, 680.	3.8	206
9	European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. Journal of Antimicrobial Chemotherapy, 2018, 73, 3221-3230.	1.3	186
10	Diagnosing COVID-19-associated pulmonary aspergillosis. Lancet Microbe, The, 2020, 1, e53-e55.	3.4	158
11	Antifungal drugs: What brings the future?. Medical Mycology, 2019, 57, S328-S343.	0.3	141
12	Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 275-285.	1.5	135
13	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. Journal of Infection, 2018, 76, 20-37.	1.7	125
14	Mechanism of Oxime Reactivation of Acetylcholinesterase Analyzed by Chirality and Mutagenesisâ€. Biochemistry, 2000, 39, 5750-5757.	1.2	116
15	Therapeutic Drug Monitoring of Voriconazole. Therapeutic Drug Monitoring, 2008, 30, 403-411.	1.0	116
16	ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children. Clinical Microbiology and Infection, 2019, 25, 1096-1113.	2.8	112
17	Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene. Antimicrobial Agents and Chemotherapy, 2010, 54, 860-865.	1.4	110
18	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Medicine, 2021, 47, 819-834.	3.9	106

#	Article	IF	Citations
19	The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Medicine, 2017, 43, 1021-1032.	3.9	100
20	The role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside. Drug Resistance Updates, 2014, 17, 37-50.	6.5	89
21	Drugâ€drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transplant Infectious Disease, 2017, 19, e12751.	0.7	89
22	Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clinical Pharmacokinetics, 2019, 58, 859-874.	1.6	82
23	Multinational Observational Cohort Study of COVID-19â€“Associated Pulmonary Aspergillosis1. Emerging Infectious Diseases, 2021, 27, 2892-2898.	2.0	82
24	Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis. Antimicrobial Agents and Chemotherapy, 2010, 54, 4758-4764.	1.4	80
25	Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP. Antimicrobial Agents and Chemotherapy, 2016, 60, 3372-3379.	1.4	80
26	Pharmacokinetics and Pharmacodynamics of Posaconazole. Drugs, 2020, 80, 671-695.	4.9	80
27	Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clinical Infectious Diseases, 2019, 68, S260-S274.	2.9	73
28	Ultraâ€small superparamagnetic iron oxides for metastatic lymph node detection: back on the block. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2018, 10, e1471.	3.3	70
29	Cost Evaluation of Dried Blood Spot Home Sampling as Compared to Conventional Sampling for Therapeutic Drug Monitoring in Children. PLoS ONE, 2016, 11, e0167433.	1.1	66
30	Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Review of Anti-Infective Therapy, 2013, 11, 931-941.	2.0	65
31	Understanding Variability in Posaconazole Exposure Using an Integrated Population Pharmacokinetic Analysis. Antimicrobial Agents and Chemotherapy, 2014, 58, 6879-6885.	1.4	65
32	Pharmacokinetics of caspofungin in ICU patients. Journal of Antimicrobial Chemotherapy, 2014, 69, 3294-3299.	1.3	61
33	Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature. Clinical Pharmacokinetics, 2020, 59, 173-205.	1.6	61
34	Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19. Journal of Infectious Diseases, 2021, 223, 1322-1333.	1.9	61
35	Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. Journal of Antimicrobial Chemotherapy, 2013, 68, 385-393.	1.3	60
36	Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice. Current Opinion in Pharmacology, 2015, 24, 38-44.	1.7	60

#	Article	IF	Citations
37	Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 2855-2866.	1.4	60
38	Paracetamol for intravenous use in medium- and intensive care patients: pharmacokinetics and tolerance. European Journal of Clinical Pharmacology, 2010, 66, 713-719.	0.8	57
39	International Interlaboratory Proficiency Testing Program for Measurement of Azole Antifungal Plasma Concentrations. Antimicrobial Agents and Chemotherapy, 2009, 53, 303-305.	1.4	56
40	Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia. Journal of Antimicrobial Chemotherapy, 2011, 66, 1853-1856.	1.3	56
41	COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion. Lancet Respiratory Medicine,the, 2021, 9, 795-802.	5.2	56
42	Clinical Pharmacokinetics and Pharmacodynamics of Micafungin. Clinical Pharmacokinetics, 2018, 57, 267-286.	1.6	55
43	Aspergillus Test Profiles and Mortality in Critically Ill COVID-19 Patients. Journal of Clinical Microbiology, 2021, 59, e0122921.	1.8	50
44	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive Care Medicine, 2021, 47, 674-686.	3.9	49
45	Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 4403-4409.	1.4	48
46	A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. Clinical Pharmacokinetics, 2018, 57, 475-489.	1.6	48
47	Therapeutic Drug Monitoring of Voriconazole in a Child With Invasive Aspergillosis Requiring Extracorporeal Membrane Oxygenation. Therapeutic Drug Monitoring, 2008, 30, 643-646.	1.0	43
48	A Twice Daily Posaconazole Dosing Algorithm for Children With Chronic Granulomatous Disease. Pediatric Infectious Disease Journal, 2011, 30, 794-797.	1.1	42
49	Impact of Therapeutic Drug Monitoring of Voriconazole in a Pediatric Population. Pediatric Infectious Disease Journal, 2011, 30, 533-534.	1.1	42
50	Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 887-888, 79-84.	1.2	41
51	Citrulline and albumin as biomarkers for gastrointestinal mucositis in recipients of hematopoietic SCT. Bone Marrow Transplantation, 2013, 48, 977-981.	1.3	41
52	Software for Dosage Individualization of Voriconazole for Immunocompromised Patients. Antimicrobial Agents and Chemotherapy, 2013, 57, 1888-1894.	1.4	40
53	Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. Clinical Infectious Diseases, 2019, 68, S244-S259.	2.9	40
54	Invasive pulmonary aspergillosis associated with viral pneumonitis. Current Opinion in Microbiology, 2021, 62, 21-27.	2.3	39

#	Article	IF	Citations
55	Dried Blood Spot Sampling for Tacrolimus and Mycophenolic Acid in Children: Analytical and Clinical Validation. Therapeutic Drug Monitoring, 2017, 39, 412-421.	1.0	38
56	Singleâ€Dose Fluconazole versus Standard 2â€Week Therapy for Oropharyngeal Candidiasis in HIVâ€Infected Patients: A Randomized, Doubleâ€Blind, Doubleâ€Dummy Trial. Clinical Infectious Diseases, 2008, 47, 1270-1276.	2.9	37
57	Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals. British Journal of Clinical Pharmacology, 2020, 86, 303-317.	1.1	37
58	Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. Journal of Antimicrobial Chemotherapy, 2010, 65, 107-113.	1.3	36
59	Impact of special patient populations on the pharmacokinetics of echinocandins. Expert Review of Anti-Infective Therapy, 2015, 13, 799-815.	2.0	36
60	Moderate correlation between systemic ILâ€6 responses and CRP with trough concentrations of voriconazole. British Journal of Clinical Pharmacology, 2018, 84, 1980-1988.	1.1	36
61	Failure of Posaconazole Therapy in a Renal Transplant Patient with Invasive Aspergillosis Due to Aspergillus fumigatus with Attenuated Susceptibility to Posaconazole. Antimicrobial Agents and Chemotherapy, 2011, 55, 3564-3566.	1.4	35
62	The role of the multidisciplinary team in antifungal stewardship. Journal of Antimicrobial Chemotherapy, 2016, 71, ii37-ii42.	1.3	35
63	Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure. Clinical Pharmacokinetics, 2016, 55, 723-733.	1.6	35
64	Highâ€dose posaconazole for azoleâ€resistant aspergillosis and other difficultâ€toâ€treat mould infections. Mycoses, 2020, 63, 122-130.	1.8	35
65	Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	33
66	Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration. Clinical Pharmacokinetics, 2017, 56, 1057-1068.	1.6	32
67	Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations. Journal of Antimicrobial Chemotherapy, 2014, 69, 2988-2994.	1.3	29
68	CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects. Journal of Clinical Pharmacology, 2017, 57, 235-246.	1.0	29
69	Pharmacokinetics of Anidulafungin in Critically Ill Intensive Care Unit Patients with Suspected or Proven Invasive Fungal Infections. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	29
70	Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. Journal of Antimicrobial Chemotherapy, 2018, 73, 134-142.	1.3	29
71	Molecular Mechanisms of 5-Fluorocytosine Resistance in Yeasts and Filamentous Fungi. Journal of Fungi (Basel, Switzerland), 2021, 7, 909.	1.5	29
72	Management of drugâ€“drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. Lancet Haematology,the, 2022, 9, e58-e72.	2.2	29

#	Article	IF	Citations
73	Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	28
74	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. Clinical Pharmacokinetics, 2020, 59, 1195-1216.	1.6	28
75	Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients. Clinical Pharmacokinetics, 2017, 56, 1197-1206.	1.6	27
76	Dried Blood Spot sampling in psychiatry: Perspectives for improving therapeutic drug monitoring. European Neuropsychopharmacology, 2017, 27, 205-216.	0.3	27
77	The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azoleâ€resistance. A nationwide survey and rationale for the <scp>DB</scp>â€<scp>MSG</scp> 002 study protocol. Mycoses, 2018, 61, 656-664.	1.8	26
78	Fundament and Prerequisites for the Application of an Antifungal TDM Service. Current Fungal Infection Reports, 2015, 9, 122-129.	0.9	25
79	Prospective validation of a modelâ€informed precision dosing tool for vancomycin in intensive care patients. British Journal of Clinical Pharmacology, 2020, 86, 2497-2506.	1.1	25
80	Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. Lancet Haematology,the, 2022, 9, e361-e373.	2.2	25
81	Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis. International Journal of Antimicrobial Agents, 2019, 54, 790-797.	1.1	24
82	Development and validation of an analytical method using UPLCâ€“MS/MS to quantify everolimus in dried blood spots in the oncology setting. Journal of Pharmaceutical and Biomedical Analysis, 2018, 149, 106-113.	1.4	23
83	Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults. Journal of Antimicrobial Chemotherapy, 2019, 74, 978-985.	1.3	23
84	A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1166-1174.	1.3	22
85	Amphotericin B and terbinafine but not the azoles prolong survival in Galleria mellonella larvae infected with Madurella mycetomatis. Medical Mycology, 2018, 56, 469-478.	0.3	22
86	Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	22
87	Analysis of cholinesterase inactivation and reactivation by systematic structural modification and enantiomeric selectivity. Chemico-Biological Interactions, 1999, 119-120, 3-15.	1.7	21
88	Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer. European Journal of Clinical Pharmacology, 2018, 74, 465-471.	0.8	20
89	Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD). European Journal of Human Genetics, 2018, 26, 1417-1423.	1.4	20
90	Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation. PLoS ONE, 2019, 14, e0213913.	1.1	20

#	Article	IF	Citations
91	Influenza Coinfection: Be(a)ware of Invasive Aspergillosis. Clinical Infectious Diseases, 2020, 70, 349-350.	2.9	20
92	Posaconazole Treatment in Hematology Patients. Therapeutic Drug Monitoring, 2012, 34, 320-325.	1.0	19
93	Prevention of ICU delirium and delirium-related outcome with haloperidol: a study protocol for a multicenter randomized controlled trial. Trials, 2013, 14, 400.	0.7	18
94	Does Weight Impact Anidulafungin Pharmacokinetics?. Clinical Pharmacokinetics, 2016, 55, 1289-1294.	1.6	18
95	The pharmacokinetics of nitrofurantoin in healthy female volunteers: a randomized crossover study. Journal of Antimicrobial Chemotherapy, 2019, 74, 1656-1661.	1.3	18
96	Implications for IV posaconazole dosing in the era of obesity. Journal of Antimicrobial Chemotherapy, 2020, 75, 1006-1013.	1.3	18
97	Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. Journal of Antimicrobial Chemotherapy, 2010, 65, 2188-2194.	1.3	17
98	Insufficient serum caspofungin levels in a paediatric patient on ECMO. Medical Mycology Case Reports, 2013, 2, 23-24.	0.7	17
99	Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	17
100	Pharmacodynamics of Anidulafungin against Clinical Aspergillus fumigatus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 303-308.	1.4	16
101	Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients. Medical Mycology, 2019, 57, 937-943.	0.3	16
102	Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals. Clinical Infectious Diseases, 2020, 70, 2213-2215.	2.9	16
103	Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis. Cell Reports Medicine, 2021, 2, 100289.	3.3	15
104	Rhizopus Oryzae Skin Infection Treated With Posaconazole in a Boy With Chronic Granulomatous Disease. Pediatric Infectious Disease Journal, 2010, 29, 578.	1.1	14
105	Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction. Transplant Infectious Disease, 2012, 14, 440-443.	0.7	14
106	Screening of the central nervous system in children with invasive pulmonary aspergillosis. Medical Mycology Case Reports, 2014, 4, 8-11.	0.7	14
107	Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients. Pediatric Transplantation, 2016, 20, 492-499.	0.5	14
108	Antifungal therapy: drugâ€“drug interactions at your fingertips. Journal of Antimicrobial Chemotherapy, 2016, 71, 285-289.	1.3	14

#	Article	IF	Citations
109	Caspofungin dosage adjustments are not required for patients with Childâ€“Pugh B or C cirrhosis. Journal of Antimicrobial Chemotherapy, 2018, 73, 2493-2496.	1.3	14
110	A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement. Clinical Pharmacokinetics, 2020, 59, 591-603.	1.6	14
111	Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. Journal of Antimicrobial Chemotherapy, 2021, 76, 1234-1241.	1.3	14
112	Pharmacokinetic drug interactions of azoles. Current Fungal Infection Reports, 2008, 2, 20-27.	0.9	13
113	Intrapulmonary Posaconazole Penetration at the Infection Site in an Immunosuppressed Murine Model of Invasive Pulmonary Aspergillosis Receiving Oral Prophylactic Regimens. Antimicrobial Agents and Chemotherapy, 2014, 58, 2964-2967.	1.4	13
114	Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis. Journal of Antimicrobial Chemotherapy, 2018, 73, 3095-3101.	1.3	13
115	Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. Pharmaceutical Research, 2019, 36, 112.	1.7	13
116	The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients. Pediatric Nephrology, 2019, 34, 507-515.	0.9	13
117	Favorable Outcome of Neonatal Cerebrospinal Fluid Shunt-Associated Candida Meningitis with Caspofungin. Antimicrobial Agents and Chemotherapy, 2013, 57, 2391-2393.	1.4	12
118	A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics. Blood, 2014, 124, 3027-3029.	0.6	12
119	Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1â€“18 Years. AAPS Journal, 2021, 23, 53.	2.2	12
120	Clinical Pharmacokinetics of Triazoles in Pediatric Patients. Clinical Pharmacokinetics, 2021, 60, 1103-1147.	1.6	12
121	Oseltamivir Dosing in Children Undergoing Hemodialysis. Clinical Infectious Diseases, 2010, 50, 1427-1428.	2.9	11
122	Pharmacokinetic Profile of Voriconazole in a Critically Ill Patient on Therapeutic Plasma Exchange. Therapeutic Drug Monitoring, 2013, 35, 141-143.	1.0	11
123	A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients. Clinical Pharmacokinetics, 2019, 58, 1333-1343.	1.6	11
124	Manual punch versus automated flow-through sample desorption for dried blood spot LC-MS/MS analysis of voriconazole. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1089, 16-23.	1.2	10
125	Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility. Clinical Pharmacology and Therapeutics, 2020, 108, 770-774.	2.3	10
126	An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients. Clinical Pharmacokinetics, 2022, 61, 907-918.	1.6	10

#	Article	IF	Citations
127	Development and validation of a fast and sensitive UHPLC-DAD assay for the quantification of nitrofurantoin in plasma and urine. Journal of Pharmaceutical and Biomedical Analysis, 2019, 174, 161-167.	1.4	9
128	The Challenge of Managing COVID-19 Associated Pulmonary Aspergillosis. Clinical Infectious Diseases, 2021, 73, e3615-e3616.	2.9	9
129	Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function. Journal of Antimicrobial Chemotherapy, 2020, 75, 3286-3292.	1.3	9
130	Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study. Clinical Pharmacokinetics, 2021, 60, 1361-1372.	1.6	9
131	High unbound flucloxacillin fraction in critically ill patients. Journal of Antimicrobial Chemotherapy, 2021, 76, 3220-3228.	1.3	9
132	Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. Clinical Pharmacokinetics, 2022, 61, 1167-1175.	1.6	9
133	Acute Endophthalmitis after Cataract Surgery: Clinical Characteristics and the Role of Intracameral Antibiotic Prophylaxis. Ophthalmology Retina, 2021, 5, 503-510.	1.2	8
134	Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B. Medical Mycology, 2020, 58, 874-880.	0.3	8
135	Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients. Microorganisms, 2021, 9, 2068.	1.6	8
136	Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis. Clinical Microbiology and Infection, 2022, 28, 1003-1009.	2.8	8
137	A Multidisciplinary Approach to Fungal Infections: One-Year Experiences of a Center of Expertise in Mycology. Journal of Fungi (Basel, Switzerland), 2020, 6, 274.	1.5	7
138	In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates. Journal of Antimicrobial Chemotherapy, 2020, 75, 2582-2586.	1.3	5
139	Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid. Antibiotics, 2021, 10, 1112.	1.5	5
140	A rare case of supraspinatus tendon rupture. Annals of Hematology, 2012, 91, 131-132.	0.8	4
141	Poor Performance of Laboratories Assaying Newly Developed Antiretroviral Agents. Therapeutic Drug Monitoring, 2014, 36, 824-827.	1.0	4
142	Itraconazole or Amphotericin B for Talaromycosis. New England Journal of Medicine, 2017, 377, 1402-1403.	13.9	4
143	Effects of dalteparin on antiâ€Xa activities cannot be predicted in critically ill COVIDâ€19 patients. British Journal of Clinical Pharmacology, 2021, , .	1.1	4
144	Pooled Population Pharmacokinetic Analysis for Exploring Ciprofloxacin Pharmacokinetic Variability in Intensive Care Patients. Clinical Pharmacokinetics, 2022, 61, 869-879.	1.6	4

#	Article	IF	Citations
145	Precision Therapy for Invasive Fungal Diseases. Journal of Fungi (Basel, Switzerland), 2022, 8, 18.	1.5	4
146	Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults. Journal of Antimicrobial Chemotherapy, 2022, 77, 2217-2226.	1.3	4
147	A preliminary study searching for the right dose of tacrolimus in very young (â‰¤4 years) renal transplant patients. Journal of Pharmacy and Pharmacology, 2016, 68, 1366-1372.	1.2	3
148	Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics. Mycoses, 2021, 64, 1111-1116.	1.8	3
149	Oral Antibiotics in Patients with Short Bowel Syndrome: Do or Donâ€™t?. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 821-823.	0.6	3
150	Variation in vancomycin dosing and therapeutic drug monitoring practices in neonatal intensive care units. International Journal of Clinical Pharmacy, 2022, 44, 564-569.	1.0	3
151	Pharmacokinetic evaluation of twice-a-week micafungin for prophylaxis of invasive fungal disease in children with acute lymphoblastic leukaemia: a prospective observational cohort study. Journal of Antimicrobial Chemotherapy, 2022, 77, 699-703.	1.3	3
152	Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSAâ€FLU study. Mycoses, 2022, 65, 656-660.	1.8	3
153	Efficacy and safety of selective decontamination of the digestive tract (SDD) to prevent recurrent hepatic cyst infections in polycystic liver disease: a retrospective case series. Journal of Antimicrobial Chemotherapy, 2020, 75, 2666-2669.	1.3	2
154	Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies. European Journal of Clinical Pharmacology, 2021, 77, 727-733.	0.8	2
155	More gastro-intestinal adverse events in non-ICU hospitalised COVID-19 patients treated with chloroquine versus hydroxychloroquine. International Journal of Infectious Diseases, 2021, 103, 402-403.	1.5	2
156	Ultra-performance liquid chromatography for quantification of amphotericin B plasma concentrations after use of liposomal amphotericin B. Journal of Antimicrobial Chemotherapy, 2021, 76, 961-966.	1.3	2
157	Pharmacokinetics and pharmacodynamics of eculizumab in individualized treatment of atypical hemolytic uremic syndrome. Immunobiology, 2016, 221, 1141.	0.8	1
158	Antifungal therapy: drugâ€“drug interactions at your fingertipsâ€”authors' response. Journal of Antimicrobial Chemotherapy, 2016, 71, 2062.2-2063.	1.3	1
159	Early postnatal gentamicin and ceftazidime treatment in normal and food restricted neonatal wistar rats: Implications for kidney development. Birth Defects Research, 2017, 109, 1228-1235.	0.8	1
160	Antifungal PK/PD in the Critically Ill. , 2018, , 213-238.		1
161	Optimisation of fluconazole therapy for the treatment of invasive candidiasis in preterm infants. Archives of Disease in Childhood, 2022, 107, 400-406.	1.0	1
162	Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children. Journal of Antimicrobial Chemotherapy, 2022, 77, 1725-1732.	1.3	1

#	Article	IF	Citations
163	1162. Antifungal Use in Immunocompromised Children in Europe: a 12-week Multicenter Modified Point prevalence Study (CALYPSO). Open Forum Infectious Diseases, 2021, 8, S672-S673.	0.4	1
164	Risk-proportionate approach to paediatric clinical trials: The legal requirements, challenges, and the way forward under the European Union Clinical Trials Regulation. Clinical Trials, 2022, , 174077452210938.	0.7	1
165	Drug-Drug Interactions in Treatment Using Azole Antifungal Agents. JAMA - Journal of the American Medical Association, 2016, 315, 2622.	3.8	0
166	A stitch in time saves nine. Lancet, The, 2019, 393, 1936.	6.3	0
167	Ciprofloxacin penetration into infected hepatic cysts in autosomal dominant polycystic kidney disease: a case report. Journal of Antimicrobial Chemotherapy, 2019, 74, 829-830.	1.3	0
168	Authorâ€™s Reply to Liu et al.: â€œPharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumabâ€• Clinical Pharmacokinetics, 2020, 59, 1645-1646.	1.6	0
169	Prophylaxis Against Invasive Fungal Disease for Neutropenic Children and Young Adults. JAMA - Journal of the American Medical Association, 2020, 323, 997.	3.8	0
170	Serum level directed itraconazole therapy in allergic bronchopulmonary aspergillosis. , 2016, , .		0
171	Reply to Kara et al., â€œMight Confounding Factors Have an Effect on Suboptimal Dosing of Fluconazole in Critically Ill Patients?â€• Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	0